Amivantamab
| Amivantamab | |
|---|---|
| Amivantamab_binding_MET_6wvz.png | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Amivantamab is a monoclonal antibody used in the treatment of certain types of non-small cell lung cancer (NSCLC). It is specifically designed to target and inhibit the activity of the epidermal growth factor receptor (EGFR) and MET proto-oncogene proteins, which are often implicated in the development and progression of cancer.
Mechanism of Action[edit]
Amivantamab is a bispecific antibody that binds to both the EGFR and MET receptors on the surface of cancer cells. By targeting these receptors, amivantamab disrupts the signaling pathways that promote tumor growth and survival. This dual inhibition is particularly beneficial in cases where tumors have developed resistance to other EGFR-targeted therapies.
Clinical Use[edit]
Amivantamab is primarily used in the treatment of NSCLC with specific genetic mutations, such as exon 20 insertion mutations in the EGFR gene. These mutations are less common but are associated with poor prognosis and limited treatment options. Amivantamab provides a targeted therapy option for patients with these mutations, offering a new avenue for treatment where traditional therapies may have failed.
Administration[edit]
Amivantamab is administered via intravenous infusion. The dosing schedule typically involves an initial loading phase followed by maintenance doses. The specific regimen may vary based on the patient's condition and response to treatment.
Side Effects[edit]
Common side effects of amivantamab include skin rash, infusion-related reactions, and paronychia. More serious adverse effects can occur, such as interstitial lung disease and hepatotoxicity, which require careful monitoring and management by healthcare professionals.
Development and Approval[edit]
Amivantamab was developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. It received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of NSCLC with EGFR exon 20 insertion mutations, based on clinical trial data demonstrating its efficacy and safety profile.
